Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 252

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents

Maayan, Lawrence, Correll, Christoph U.·2011·Journal of Child and Adolescent Psychopharmacology

Abstract

BACKGROUND: Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth. METHODS: Review of randomized, cohort, and pharmacoepidemiologic studies of antipsychotic-related weight gain and metabolic adverse effects and of interventions for their reduction in youth. RESULTS: Across 34 published head-to-head and placebo-controlled studies in youth with psychotic and bipolar disorders, weight gain ranged from 3.8 to 16.2 kg with olanzapine (n=353), 0.9-9.5 kg with clozapine (n=97), 1.9-7.2 kg with risperidone (n=571), 2.3-6.1 kg with quetiapine (n=133), and 0-4.4 kg with aripiprazole (n=451). In 24 placebo-controlled trials, the numbers-needed-to-harm for weight gain ≥7% in youth with bipolar disorder and schizophrenia were 39 (confidence interval [CI]: -1 to +6, not significant) for aripiprazole, 36 (CI: -1 to +7, not significant) for ziprasidone, 9 (CI: 7-14) for quetiapine, 6 (CI: 5-8) for risperidone, and 3 (CI: 3-4) for olanzapine. Data in youth with autism and disruptive behavior disorders, available only for some antipsychotics, suggest greater weight gain, possibly due to less prior antipsychotic exposure. Three-month results from a large cohort study in antipsychotic-naïve youth indicated that metabolic effects differ among second-generation antipsychotics, despite significant weight gain with all studied agents, suggesting additional, weight-independent effects. Further, pharmacoepidemiologic work indicates that antipsychotic polypharmacy increases the risk for obesity (odds ratio [OR]: 2.28 [CI: 1.49-3.65]) or any cardiovascular, cerebrovascular, or hypertensive adverse event (OR: 1.72 [CI: 1.10-2.69]). However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited. CONCLUSIONS: More research is needed to develop strategies to minimize antipsychotic-related weight gain and metabolic effects in youth and to discover treatments with lower risk potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cap.2011.0015

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 13

  1. Arman S, 2008, Saudi Med J, 29, 1130
  2. Chang KD, 2008, J Clin Psychiatry, 69, 4
  3. Colton CW, 2006, Prev Chronic Dis, 3, A42
  4. De Hert M, 2011, Nat Rev Endocrinol
  5. DelBello M, 2007, Presented at 46th Annual Meeting of the American College of Neuropsychopharmacology
  6. DelBello M, 2008, Presented at 63rd Annual Meeting of the Society of Biological Psychiatry
  7. Findling R, 2008, Presented at 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry
  8. Findling RL, 2010, J Am Acad Child Adolesc Psychiatry, 49, 583
  9. Findling RL, 2008, Presented at 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry
  10. Freeman-Fobbs P, 2003, J Natl Med Assoc, 95, 119
  11. Maayan L, 2010, Presented at New Clinical Drug Evaluation Unit 50th Anniversary Meeting
  12. McDougle CJ, 2008, J Clin Psychiatry, 69, 15
  13. 10.1034/j.1399-5448.2000.010106.x · doi:10.1034/j.1399-5448.2000.010106.x

Cited by

See all 252

Metadata

Authors
Maayan, L., & Correll, C. U.
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2011-12
Volume
21
Issue
6
Pages
517-535
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W2041413669
Cited by
252
References
106
FWCI
13.99
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.